ArticleNature communications2025
Engineering a streamlined virus-like particle for programmable tissue-specific gene delivery.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Virus-Like Particles as a Nonviral CRISPR/Cas Editing Delivery Tool.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Non-Viral CRISPR carriers: transient delivery with lasting effects.Drug delivery · 2026Review
- A versatile VLP-mediated CRISPR-RNP platform for precise genome editing and durable epigenome silencing in cancer.Molecular therapy. Nucleic acids · 2026Article
- Research Progress, Application, and Industrialization Prospects of Circular RNA Vaccines in Viral Diseases.Vaccines · 2026Review
- Restoration of the immune system with base editing and non-genotoxic conditioning in a Rag2 point-mutant mouse model.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Protein Nanocages as Versatile Vectors for Nucleic Acid Delivery: Main Systems and Their Loading Mechanisms.Molecular biotechnology · 2026Review
- From mechanism to medicine: CRISPR‒Cas9 delivery strategies, therapeutic applications and translation challenges.Discover nano · 2026Review
- Review
- Virus-like particles based on plant viruses and bacteriophages: emerging strategies for the delivery of nucleic acid therapeutics.Chemical science · 2026Review
- A novel approach to HPV16 VLP construction and production with improved accessibility and particle sorting potential.Frontiers in molecular medicine · 2026Article
- Advancements in CRISPR-basedFrontiers in genome editing · 2026Review
- mRNA vaccine platforms and novel delivery systems: From mechanistic principles to clinical translation.Human vaccines & immunotherapeutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Transient gene delivery vehicles have emerged as crucial tools in biomedicine, among them, virus-like particles (VLPs) stand out for their unique characteristics, yet the limited tropisms hinder their widespread applications. VLPs have potential to broaden their targeting range through the acquisition of programmable tropisms, however, current retrovirus-based VLPs pose engineering challenges due to multiple viral proteins. Here, we streamline the VLP system by customizing a backbone utilizing positive-strand Semliki Forest Virus (SFV) for a programmable VLP vector, minimizing virus-derived composition. The vector accommodates mRNA, protein, or ribonucleoprotein (RNP) cargos, supporting mRNA ranging from 500 bp to 10 kb. Through the engineering of the envelope protein (Env) via rational peptide insertion or pseudotyping with other fusogens, we generate VLP candidates exhibiting enhanced in vivo blood-brain barrier (BBB) penetration, expanded in vitro targeting ranges and the ability to escape neutralizing antibodies (Nab), or muscle-targeting capabilities. The programmable engineering capabilities and customizable tropisms provide the possibility and flexibility to be tailored for diverse treatment strategies in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.